{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:59:24Z","timestamp":1792828764634,"version":"4.5.0"},"reference-count":40,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2007,8,10]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> By monitoring bone metastases with sequential [<jats:sup>18<\/jats:sup>F]fluorodeoxyglucose positron-emission tomography\/computed tomography ([<jats:sup>18<\/jats:sup>F]FDG-PET\/CT) imaging, this study investigates the clinical relevance of [<jats:sup>18<\/jats:sup>F]FDG uptake features of bone metastases with various radiographic appearances. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Bone metastases were found in 67 of 408 consecutive patients with known\/suspected recurrent breast cancer on [<jats:sup>18<\/jats:sup>F]FDG-PET\/CT, characterized by CT morphology changes and\/or bony [<jats:sup>18<\/jats:sup>F]FDG uptake. Twenty-five of the patients had sequential [<jats:sup>18<\/jats:sup>F]FDG-PET\/CT examinations (86 studies) over an average follow-up period of 23 months. The temporal changes in [<jats:sup>18<\/jats:sup>F]FDG uptake and corresponding CT morphology features of 146 bone lesions identified in these 25 patients were followed up and correlated with therapeutic outcome retrospectively. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> The 146 lesions were classified as osteolytic (77), osteoblastic (41), mixed-pattern (11), or no change\/negative (17) on CT. The majority of the osteolytic (72; 93.5%) and mixed-pattern lesions (nine; 81.8%), but fewer of the osteoblastic lesions (25; 61%), showed increased [<jats:sup>18<\/jats:sup>F]FDG uptake. After treatment, 58 osteolytic lesions (80.5%) became [<jats:sup>18<\/jats:sup>F]FDG negative and osteoblastic on CT and only 14 relatively large lesions (19.5%) remained [<jats:sup>18<\/jats:sup>F]FDG avid. Of the 25 [<jats:sup>18<\/jats:sup>F]FDG-avid osteoblastic lesions, 13 (52%) became [<jats:sup>18<\/jats:sup>F]FDG negative, but 12 (48%) remained [<jats:sup>18<\/jats:sup>F]FDG avid and increased in size on CT. Five of the mixed-pattern lesions remained [<jats:sup>18<\/jats:sup>F]FDG avid after treatment. All 17 CT-negative lesions became [<jats:sup>18<\/jats:sup>F]FDG negative; however, nine of them became osteoblastic. None of the initially [<jats:sup>18<\/jats:sup>F]FDG-negative lesions showed [<jats:sup>18<\/jats:sup>F]FDG avidity during follow-up. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> [<jats:sup>18<\/jats:sup>F]FDG uptake reflects the immediate tumor activity of bone metastases, whereas the radiographic morphology changes vary greatly with time among patients. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2007.11.2854","type":"journal-article","created":{"date-parts":[[2007,6,26]],"date-time":"2007-06-26T01:11:04Z","timestamp":1182820264000},"page":"3440-3447","source":"Crossref","is-referenced-by-count":152,"title":["Fusion of Metabolic Function and Morphology: Sequential [<sup>18<\/sup>F]Fluorodeoxyglucose Positron-Emission Tomography\/Computed Tomography Studies Yield New Insights Into the Natural History of Bone Metastases in Breast Cancer"],"prefix":"10.1200","volume":"25","author":[{"given":"Yong","family":"Du","sequence":"first","affiliation":[{"name":"From the Institute of Nuclear Medicine, University College London Hospitals National Health Service Foundation Trust, and University College London, London; and the Cancer and Imaging School, University of Manchester and Christie Hospital National Health Service Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Cullum","sequence":"additional","affiliation":[{"name":"From the Institute of Nuclear Medicine, University College London Hospitals National Health Service Foundation Trust, and University College London, London; and the Cancer and Imaging School, University of Manchester and Christie Hospital National Health Service Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim M.","family":"Illidge","sequence":"additional","affiliation":[{"name":"From the Institute of Nuclear Medicine, University College London Hospitals National Health Service Foundation Trust, and University College London, London; and the Cancer and Imaging School, University of Manchester and Christie Hospital National Health Service Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Ell","sequence":"additional","affiliation":[{"name":"From the Institute of Nuclear Medicine, University College London Hospitals National Health Service Foundation Trust, and University College London, London; and the Cancer and Imaging School, University of Manchester and Christie Hospital National Health Service Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050276"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2382041977"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1259\/bjr\/18454286"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-005-1869-x"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2004.11.005"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Williams HT, Smith S: FDG PET and SPECT of bone metastases in breast cancer. AJR Am J Roentgenol 185:1651,2005-1652,","DOI":"10.2214\/AJR.05.5157"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra030831"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.3.509"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.5-6-463"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.931"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.060"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199612123352401"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.34066"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.3490"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.181"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2005.09.002"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3375"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.184.4.01841266"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-005-1842-8"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1007\/BF02985050"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1097\/00003072-200503000-00017"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-006-0141-3"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.213.2.r99nv37521"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7172.1572"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7447.1073"},{"key":"R27","unstructured":"Shankar LK, Hoffman JM, Bacharach S, et al: Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47:1059,2006-1066,"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11132"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1856"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.15.3562"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.10746"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3534"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2372031994"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-006-0361-8"},{"key":"R35","unstructured":"Metser U, Lerman H, Blank A, et al: Malignant involvement of the spine: Assessment by 18F-FDG PET\/CT. J Nucl Med 45:279,2004-284,"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1016\/S1076-6332(03)80461-0"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Specht JM, Tam SL, Kurland BF, et al: Serial 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat  [epub ahead of print on February 1, 2007]","DOI":"10.1007\/s10549-006-9435-1"},{"key":"R38","unstructured":"Miller TR, Wallis JW, Grothe RA Jr: Design and use of PET tomographs: The effect of slice spacing. J Nucl Med 31:1732,1990-1739,"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602464"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2431052104"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2007.11.2854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:08:09Z","timestamp":1653509289000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2007.11.2854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,10]]},"references-count":40,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2007,8,10]]}},"alternative-id":["10.1200\/JCO.2007.11.2854"],"URL":"https:\/\/doi.org\/10.1200\/jco.2007.11.2854","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,10]]}}}